Background. The implementation of outpatient parenteral antimicrobial therapy (OPAT) programs has increased due to the benefits of reduced cost with equivalent clinical outcomes compared to inpatient care. The purpose of this study is to evaluate the outcomes, both efficacy and adverse effects, of our program. Secondarily, a pharmacoeconomic analysis was performed to compare costs of the program to inpatient hosiptal care or rehabilitation.
Methods. This study is a retrospective chart review of 98 courses of OPAT between April 2011 and July 2013 to determine success rate and risk factors for failure. Clinical failures were defined as readmission during therapy, readmission within 3 months after discontinuation, or death. Failure due to adverse drug event (ADE) was defined as premature discontinuation, antibiotic switch, or readmission due to ADE. Baseline characteristics and program specific data were analyzed to determine variables that may affect outcome. Statistically significant variables were built into a multivariate logistic regression model to determine factors predictive of OPAT failure. A pharmacoeconomic analysis of this program was performed using billing records.
Results. Overall there were 43 failures (43.9%) and 55 successes (56.1%). Of the total failures, 27.9% were due to ADE, 25.6% to therapy failure, 34.9% to comorbidities, and 11.6% to miscellaneous causes. In the multivariate analysis, shorter duration of therapy was associated with a higher chance of failure ( p = 0.0003). Eosinophilia was also a predictor of failure ( p = 0.0026). The total cost of the program was $610,344. When compared to inpatient or rehabilitation care during the same period, the cost savings was $10,201,386 or $2,657,531, respectively.
Conclusion. OPAT is becoming an increasingly important option that is safe and effective for managing patients who require long-term use of intravenous antimicrobials. In our study, patients tolerated OPAT well, with a low number of failures due to ADE. Eosinophilia and shorter duration of treatment were associated with higher rates of failure. The clinical outcomes and cost savings of our program demonstrate that OPAT can be a viable alternative to long-term inpatient antimicrobial therapy.
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